VÃ©ronique Avettand-Fenoel

List of Publications by Year
in descending order

148 papers	6,564 citations	66234 42 h-index	71532 76 g-index
157 all docs	157 docs citations	157 times ranked	6996 citing authors

#	Article	IF	Citations
1	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathogens, 2013, 9, e1003211.	2.1	879
2	Enhanced T cell recovery in HIV-1â€“infected adults through IL-7 treatment. Journal of Clinical Investigation, 2009, 119, 997-1007.	3.9	288
3	Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. PLoS ONE, 2009, 4, e6093.	1.1	222
4	Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study. Clinical Infectious Diseases, 2012, 55, 291-300.	2.9	209
5	Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. Journal of Antimicrobial Chemotherapy, 2013, 68, 1169-1178.	1.3	208
6	LTR realâ€time PCR for HIVâ€1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). Journal of Medical Virology, 2009, 81, 217-223.	2.5	195
7	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. PLoS Pathogens, 2015, 11, e1005153.	2.1	191
8	Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clinical Microbiology Reviews, 2016, 29, 859-880.	5.7	185
9	Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses. Journal of Immunology, 2009, 182, 7828-7837.	0.4	183
10	Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids, 2010, 24, 1598-1601.	1.0	179
11	Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study. PLoS ONE, 2008, 3, e3907.	1.1	171
12	HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV,the, 2016, 3, e49-e54.	2.1	131
13	Impact of Norovirus/Sapovirus-Related Diarrhea in Renal Transplant Recipients Hospitalized for Diarrhea. Transplantation, 2011, 92, 61-69.	0.5	130
14	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. Cell Metabolism, 2019, 29, 611-626.e5.	7.2	124
15	The Kidney as a Reservoir for HIV-1 after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2014, 25, 407-419.	3.0	121
16	Immune Responses Driven by Protective Human Leukocyte Antigen Alleles From Long-term Nonprogressors Are Associated With Low HIV Reservoir in Central Memory CD4 T Cells. Clinical Infectious Diseases, 2012, 54, 1495-1503.	2.9	110
17	Elite controllers as a model of functional cure. Current Opinion in HIV and AIDS, 2011, 6, 181-187.	1.5	108
18	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of Antimicrobial Chemotherapy, 2015, 70, 2108-2120.	1.3	92

#	ARTICLE	IF	CITATIONS
19	Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis. Nature Communications, 2017, 8, 15264.	5.8	77
20	Sequential treatment with 5â€zaâ€2â€²â€deoxycytidine and deacetylase inhibitors reactivates <scp>HIV</scp>â€1. EMBO Molecular Medicine, 2016, 8, 117-138.	3.3	73
21	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infectious Diseases, The, 2015, 15, 387-396.	4.6	67
22	Prospective Identification of Congenital Cytomegalovirus Infection in Newborns Using Real-Time Polymerase Chain Reaction Assays in Dried Blood Spots. Clinical Infectious Diseases, 2011, 52, 575-581.	2.9	66
23	Prevalence and Clinical Impact of Norovirus Fecal Shedding in Children with Inherited Immune Deficiencies. Journal of Infectious Diseases, 2012, 206, 1269-1274.	1.9	65
24	Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. Journal of Experimental Medicine, 2020, 217, .	4.2	64
25	A Single HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV among Resting CD4+ Cell Subsets within One Month Post-Infection. PLoS ONE, 2013, 8, e64219.	1.1	63
26	Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunology, 2015, 8, 127-140.	2.7	63
27	Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 1046-1050.	1.3	59
28	Spatiotemporal dynamics of HIV-1 transmission in France (1999â€“2014) and impact of targeted prevention strategies. Retrovirology, 2017, 14, 15.	0.9	59
29	Use of Genotypic Identification by sodA Sequencing in a Prospective Study To Examine the Distribution of Coagulase-Negative Staphylococcus Species among Strains Recovered during Septic Orthopedic Surgery and Evaluate Their Significance. Journal of Clinical Microbiology, 2005, 43, 2952-2954.	1.8	57
30	HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. Journal of Clinical Virology, 2008, 42, 399-404.	1.6	55
31	HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. Aids, 2008, 22, 1880-1882.	1.0	55
32	Increasing HIV-1 Non-B Subtype Primary Infections in Patients in France and Effect of HIV Subtypes on Virological and Immunological Responses to Combined Antiretroviral Therapy. Clinical Infectious Diseases, 2013, 56, 880-887.	2.9	55
33	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE, 2011, 6, e18726.	1.1	52
34	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1507-1512.	1.3	52
35	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. Journal of Virology, 2016, 90, 6148-6158.	1.5	50
36	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral â€œblipsâ€•and Immune Activation in the ANRS CO21 CODEX Study. PLoS ONE, 2015, 10, e0131922.	1.1	50

#	Article	IF	Citations
37	Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical Infectious Diseases, 2019, 69, 1498-1505.	2.9	49
38	Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification. Journal of Clinical Microbiology, 2010, 48, 1413-1416.	1.8	47
39	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infectious Diseases, 2017, 4, ofx064.	0.4	45
40	HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. EBioMedicine, 2017, 21, 158-169.	2.7	45
41	Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers. Transplantation Proceedings, 2013, 45, 1603-1607.	0.3	43
42	Genotypic resistance profiles of HIV-2-treated patients in West Africa. Aids, 2014, 28, 1161-1169.	1.0	43
43	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007â€“12: impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2015, 70, 2084-2089.	1.3	42
44	NKG2C⁺ memoryâ€like NK cells contribute to the control of HIV viremia during primary infection: Optiprimâ€ANRS 147. Clinical and Translational Immunology, 2017, 6, e150.	1.7	42
45	Total HIV DNA: a global marker of HIV persistence. Retrovirology, 2018, 15, 30.	0.9	42
46	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 ⁺ T Cell Response in HIV Controllers. Journal of Virology, 2014, 88, 176-187.	1.5	39
47	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. American Journal of Transplantation, 2020, 20, 3462-3476.	2.6	38
48	Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus Infection. Journal of Clinical Microbiology, 2006, 44, 2250-2253.	1.8	36
49	Early Control of HIV-1 Infection in Long-Term Nonprogressors Followed Since Diagnosis in the ANRS SEROCO/HEMOCO Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 19-26.	0.9	33
50	Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. Aids, 2007, 21, 776-777.	1.0	32
51	Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children. Journal of Pediatrics, 2013, 162, 593-599.	0.9	31
52	Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers. Aids, 2014, 28, 1567-1577.	1.0	30
53	A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART. Frontiers in Immunology, 2017, 8, 54.	2.2	30
54	Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. Aids, 2017, 31, 181-189.	1.0	29

#	Article	IF	Citations
55	Use of sodA sequencing for the identification of clinical isolates of coagulase-negative staphylococci. Clinical Microbiology and Infection, 2004, 10, 939-942.	2.8	28
56	Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3. MBio, 2018, 9, .	1.8	28
57	Relationships Between HIV Disease History and Blood HIV-1 DNA Load in Perinatally Infected Adolescents and Young Adults: The ANRS-EP38-IMMIP Study. Journal of Infectious Diseases, 2012, 205, 1520-1528.	1.9	26
58	Quantification of Total HIV1-DNA in Peripheral Blood Mononuclear Cells. Methods in Molecular Biology, 2014, 1087, 261-270.	0.4	26
59	Polyfunctional HIV-specific T cells in Post-Treatment Controllers. Aids, 2016, 30, 2299-2302.	1.0	26
60	Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2018, 66, 1519-1527.	2.9	25
61	Impact of early cART on HIV blood and semen compartments at the time of primary infection. PLoS ONE, 2017, 12, e0180191.	1.1	25
62	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. Leukemia, 2021, 35, 764-776.	3.3	24
63	Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART. Journal of Medical Virology, 2011, 83, 1499-1507.	2.5	23
64	Adenoviral Infection Presenting as an Isolated Central Nervous System Disease without Detectable Viremia in Two Children after Stem Cell Transplantation. Journal of Clinical Microbiology, 2011, 49, 2361-2364.	1.8	23
65	New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load. Journal of Clinical Microbiology, 2014, 52, 3017-3022.	1.8	23
66	Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. Leukemia, 2017, 31, 2532-2535.	3.3	22
67	Ageing with <scp>HIV</scp>: do comorbidities and polymedication drive treatment optimization?. HIV Medicine, 2017, 18, 395-401.	1.0	22
68	Mass Cytometry Analysis Reveals the Landscape and Dynamics of CD32a+ CD4+ T Cells From Early HIV Infection to Effective cART. Frontiers in Immunology, 2018, 9, 1217.	2.2	22
69	Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection. EBioMedicine, 2020, 62, 103129.	2.7	22
70	Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nature Communications, 2022, 13, 521.	5.8	22
71	Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. Journal of Antimicrobial Chemotherapy, 2010, 65, 1005-1007.	1.3	21
72	Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration. PLoS ONE, 2015, 10, e0129886.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. Journal of Antimicrobial Chemotherapy, 2015, 70, 1921-1923.	1.3	21
74	Dynamics in HIVâ€ÐNA levels over time in HIV controllers. Journal of the International AIDS Society, 2019, 22, e25221.	1.2	21
75	Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. Aids, 2012, 26, 711-720.	1.0	20
76	Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology, 2020, 17, 5.	0.9	20
77	Short Communication: Evidence of HIV Type 1 Complex and Second Generation Recombinant Strains Among Patients Infected in 1997â€“2007 in France: ANRS CO06 PRIMO Cohort. AIDS Research and Human Retroviruses, 2010, 26, 645-651.	0.5	19
78	HIV-mediated immune aging in young adults infected perinatally or during childhood. Aids, 2019, 33, 1705-1710.	1.0	19
79	Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children. Pediatric Infectious Disease Journal, 2011, 30, 684-688.	1.1	18
80	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. Journal of Antimicrobial Chemotherapy, 2016, 71, 751-761.	1.3	18
81	Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 605-613.	0.9	18
82	Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE). Journal of Antimicrobial Chemotherapy, 2010, 65, 2212-2214.	1.3	17
83	Naive T Lymphocytes and Recent Thymic Emigrants Are Associated With HIV-1 Disease History in French Adolescents and Young Adults Infected in the Perinatal Period: The ANRS-EP38-IMMIP Study. Clinical Infectious Diseases, 2014, 58, 573-587.	2.9	17
84	Predominance of G9P[8] rotavirus strains throughout France, 2014â€“2017. Clinical Microbiology and Infection, 2018, 24, 660.e1-660.e4.	2.8	17
85	Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. Journal of Antimicrobial Chemotherapy, 2009, 64, 433-434.	1.3	15
86	Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw464.	1.3	15
87	HIV Infection in the Native and Allograft Kidney. Transplantation, 2017, 101, 2003-2008.	0.5	15
88	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clinical Infectious Diseases, 2018, 66, 1588-1594.	2.9	15
89	New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. Journal of Clinical Microbiology, 2017, 55, 2850-2857.	1.8	14
90	HIV controllers: to treat or not to treat? Is that the right question?. Lancet HIV,the, 2019, 6, e878-e884.	2.1	13

#	Article	IF	Citations
91	HIV DNA. Current Opinion in HIV and AIDS, 2018, 13, 389-394.	1.5	12
92	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial Chemotherapy, 2019, 74, 1417-1424.	1.3	12
93	Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. EBioMedicine, 2019, 41, 455-464.	2.7	12
94	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell Reports, 2020, 32, 108174.	2.9	12
95	CCR5 antagonists. Aids, 2012, 26, 1673-1677.	1.0	11
96	Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. Annals of Hematology, 2021, 100, 2813-2824.	0.8	11
97	Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies. Journal of Medical Virology, 2017, 89, 2047-2050.	2.5	10
98	Similar efficacy and safety of dolutegravir between age groups of HIV â€1â€infected paediatric and young adult patients aged 5Âyears and older. HIV Medicine, 2019, 20, 561-566.	1.0	10
99	Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIVâ€1 infection: results from a longitudinal study in the French ANRS Primo cohort. Journal of the International AIDS Society, 2020, 23, e25485.	1.2	10
100	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine, 2022, 79, 103985.	2.7	10
101	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. Frontiers in Immunology, 2020, 11, 604353.	2.2	9
102	Impact of Early Versus Late Antiretroviral Treatment Initiation on Naive T Lymphocytes in HIV-1-Infected Children and Adolescents â€“ The-ANRS-EP59-CLEAC Study. Frontiers in Immunology, 2021, 12, 662894.	2.2	9
103	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	1.5	9
104	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. Journal of Antimicrobial Chemotherapy, 2015, 70, 566-572.	1.3	8
105	Clinical severity and molecular characteristics of circulating and emerging rotaviruses in young children attending hospital emergency departments in France. Clinical Microbiology and Infection, 2016, 22, 737.e9-737.e15.	2.8	8
106	What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. EBioMedicine, 2018, 27, 51-60.	2.7	8
107	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. Journal of Antimicrobial Chemotherapy, 2020, 75, 183-193.	1.3	8
108	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a singleâ€center experience. Transplant International, 2019, 32, 481-492.	0.8	8

#	ARTICLE	IF	CITATIONS
109	HIV-DNA in the Genital Tract of Women on Long-Term Effective Therapy Is Associated to Residual Viremia and Previous AIDS-Defining Illnesses. PLoS ONE, 2013, 8, e69686.	1.1	8
110	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. Journal of Antimicrobial Chemotherapy, 2017, 72, 2351-2354.	1.3	7
111	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transplant Infectious Disease, 2018, 20, e12846.	0.7	7
112	Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006â€“17): impact on susceptibility to first-line strategies. Journal of Antimicrobial Chemotherapy, 2018, 73, 2475-2479.	1.3	7
113	Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance. HIV Medicine, 2021, 22, 958-964.	1.0	7
114	Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 2506-2515.	1.3	7
115	High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection. Journal of Antimicrobial Chemotherapy, 2017, 72, 2681-2683.	1.3	6
116	Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?. Journal of Antimicrobial Chemotherapy, 2020, 75, 1324-1331.	1.3	6
117	Long-Term HIV-1 Virologic Control in Patients on a Dual NRTI Regimen. HIV Clinical Trials, 2013, 14, 120-126.	2.0	5
118	Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant. Journal of Clinical Virology, 2018, 99-100, 57-60.	1.6	5
119	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	3.2	5
120	HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278). Journal of Antimicrobial Chemotherapy, 2014, 69, 3047-3050.	1.3	4
121	Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 2627-2631.	1.3	4
122	Comparative risk of failure of <scp>ABC</scp>/3<scp>TC</scp> or <scp>TDF</scp>/<scp>FTC</scp> based firstâ€line regimens in patients with a high viral load. HIV Medicine, 2016, 17, 380-384.	1.0	4
123	Does Changing Antiretroviral Therapy in the First Trimester of Pregnancy for Safety Concerns Have an Impact on Viral Suppression?. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 574-584.	0.9	4
124	Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen. Journal of Antimicrobial Chemotherapy, 2019, 74, 718-721.	1.3	4
125	High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents. MÃ©decine Et Maladies Infectieuses, 2020, 50, 269-273.	5.1	4
126	Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence. Clinical Infectious Diseases, 2021, 73, e4214-e4222.	2.9	4

#	ARTICLE	IF	CITATIONS
127	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, 77, 735-739.	1.3	4
128	Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains. Journal of Clinical Virology, 2019, 110, 36-41.	1.6	3
129	Genital Human Immunodeficiency Virusâ€“1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials. Clinical Infectious Diseases, 2020, 70, 1973-1979.	2.9	3
130	Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity â€" The ANRS-EP38-IMMIP Study. PLoS ONE, 2015, 10, e0144706.	1.1	2
131	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). Journal of Antimicrobial Chemotherapy, 2016, 71, 490-496.	1.3	2
132	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. Nephrology Dialysis Transplantation, 2019, 34, 1597-1604.	0.4	2
133	Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 1564-1572.	1.3	2
134	CXCR3 and CXCR5 are highly expressed in HIVâ€1â€specific CD8 central memory TÂcells from infected patients. European Journal of Immunology, 2021, 51, 2040-2050.	1.6	2
135	The Coris BioConcept COVID 19 Ag Respi-Strip, a field experience feedback. Journal of Virological Methods, 2022, 300, 114366.	1.0	2
136	S03-04 OA. Transitional and central memory CD4 T cells are highly infected in long term non progressors and elite controllers. Retrovirology, 2009, 6, .	0.9	1
137	Gag-Specific CD4 T Cell Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected Youths: The ANRS-EP38-IMMIP Study. AIDS Research and Human Retroviruses, 2017, 33, 21-28.	0.5	1
138	Poor palatability of the new ritonavir formulation is a major obstacle to adherence to treatment in young children. Journal of Antimicrobial Chemotherapy, 2018, 73, 1435-1437.	1.3	1
139	Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1020-1024.	1.3	1
140	The proportion of CD57+ cells among effector CD8+ T cells is lower in HIV controllers compared with antiretroviral therapy-treated patients. Aids, 2019, 33, 2137-2147.	1.0	1
141	False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers. Clinical Infectious Diseases, 2020, 70, 1754-1757.	2.9	1
142	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.3	1
143	Immunoblots may not be effective in confirming the recency of HIV-1 infection. Journal of Virological Methods, 2021, 290, 114074.	1.0	1
144	476 Reasons for the lack of anti-HBc antibody detection in hepatitis B virus infected patients. Journal of Hepatology, 2006, 44, S177.	1.8	0

#	ARTICLE	IF	CITATIONS
145	Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children. Obstetrical and Gynecological Survey, 2013, 68, 501-503.	0.2	0
146	Gag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor-Î² and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study. Open Forum Infectious Diseases, 2017, 4, ofw239.	0.4	0
147	MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE-TYPE AND IS A THERAPEUTIC TARGET IN ADULT T-CELL LEUKEMIA/LYMPHOMA. Hematological Oncology, 2019, 37, 271-272.	0.8	0
148	Immune responses and latent tissue reservoirs during the course of HIV-1 infection. Virologie, 2013, 17, 157-168.	0.1	0